Nature of Business (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 02, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Nature of Business (Textual)
Cash and cash equivalents		$ 4,244,871	$ 5,813,863	$ 4,244,871	$ 5,813,863	$ 7,809,487	$ 8,772,567
Net decrease in cash and cash equivalents				$ (3,564,616)	(2,958,704)
Percentage decrease in cash and cash equivalents				46.00%
Cash used in operations				$ (3,601,092)	(2,979,673)
Working capital		2,369,324		2,369,324		6,185,863
Decrease in working capital				$ 3,816,539
Percentage of decrease in working capital				62.00%
Government contract and grant funding available				$ 17,300,000
Net proceeds from the sale of NJ NOL				416,810
Equity facility, available amount		10,100,000		$ 10,100,000
Equity facility expiration date				Mar. 31, 2019
Accumulated deficit		(161,203,593)		$ (161,203,593)		$ (157,270,045)
Net loss		$ (1,556,342)	$ (2,311,598)	$ (3,933,548)	$ (4,045,035)
Contracts from BARDA and NIAID, description				The Company is currently developing RiVax® under a NIH contract of up to $24.7 million, and SGX301 and SGX942 under two separate NIH grants of approximately $1.5 million each over two years.
Subsequent Event [Member]
Nature of Business (Textual)
Aggregate Gross Proceeds Of Common Stock And Warrants	$ 9,200,000